It looks like nothing was found at this location. Maybe try one of the links below or a search?
Popular Articles:
-
Response to EPO consultation: Don’t impose oral proceedings by videoconference
-
Quality at the EPO – One Modest and one Serious Proposal
-
‘Opposition against Unitary Patent comes from fearful lawyers and critics who only have a theoretical interest’
-
Leading German patent law firms criticize European Patent Office
-
UPC: four reasons on why the PPA is not legally in force
-
The EPO’s Vision (V) – Trust
Recent Articles:
-
Announcement of the national program “MOVER” raises expectations for an increase in patent filings for green technology
-
UPC “saisie-contrefaçon” Part III: the “C-Kore” case
-
Brazil: Animal Health and Patent Litigation
-
China’s Supreme People Court decides FRAND dispute in ACT v Oppo
-
UPC “saisie-contrefaçon” Part II: the “OERLIKON” case
-
UPC “saisie-contrefaçon” Part I: the texts
Random Articles:
-
From "in foro interno, in foro externo" to "non foro interno, in foro externo": Is the CJEU constructing the patent house from the roof down?
-
Dr. iur. et lic. rer. pol. Catherine Chammartin new Director General of Swiss Federal Office of Intellectual Property
-
Conflicts between UPCA and national laws: a dangerous riddle?
-
The Evolution of IP Management
-
Hydrogen-absorbing composition/PRYSMIAN, European Patent Office (EPO Board of Appeal), 14 May 2009
-
Patent case: Bremsbelag (Brake lining), Germany
-
Parliamentary committee asks UK government to clarify position on Unified Patent Court
-
Germany: Kreuzgestänge, Federal Court of Justice of Germany, X ZR 103/13, 2 June 2015
-
Added matter, Amendments, Case Law, Infringement, Litigation, Patents, Pharma, Pharmaceutical patent, Plausibility, Revocation, Sufficiency of disclosure, United Kingdom, Validity
Gilead Sciences v NuCana – two trials for the price of one (or two)
-
More honour’d in the breach than the observance